This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Investing in Thermo Fisher (TMO)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Explore how Thermo Fisher's (TMO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Beat the Market the Zacks Way: Oracle, Credo Tech, Palantir in Focus
by Abhinab Dasgupta
Oracle, Credo Tech, and Palantir shine in volatile markets, leading Zacks portfolios with standout gains and upgraded outlooks.
Cigna Q2 Earnings Beat Estimates on Higher Specialty Volumes
by Zacks Equity Research
CI's Q2 earnings benefit from strong Evernorth Health Services unit, offsetting customer losses and rising costs. It continues to expect 2025 adjusted EPS at a minimum of $29.60.
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
ISRG's Gross Margin Falls on Product Transition and Trade Pressures
by Indrajit Bandyopadhyay
Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.
Company News for Jul 24, 2025
by Zacks Equity Research
Companies In The News Are: T, TMO, GD, BSX.
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
by Zacks Equity Research
TMO tops Q2 estimates as new product launches and solid segment growth fuel revenue gains despite margin pressure.
Thermo Fisher (TMO) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Thermo Fisher Scientific (TMO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of +2.68% and +1.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ISRG Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Zacks Equity Research
Intuitive Surgical's second-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Thermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus
by Zacks Equity Research
Thermo Fisher eyes second-quarter 2025 growth with new tech launches in Analytical Instruments and Life-Science Solutions segments.
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Thermo Fisher Stock?
by Zacks Equity Research
Investors need to pay close attention to TMO stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR
by Zacks Equity Research
SAP, NVO, TMO and FONR navigate growth and headwinds as analysts spotlight cloud momentum, obesity drugs, and innovation plays.
Top Research Reports for SAP, Novo Nordisk & Thermo Fisher
by Mark Vickery
SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
by Zacks Equity Research
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
by Moumi Mondal
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
by Zacks Equity Research
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
by Zacks Equity Research
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
by Zacks Equity Research
TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.
Zacks Investment Ideas feature highlights: Thermo Fisher Scientific and Lululemon
by Zacks Equity Research
Thermo Fisher and Lululemon trade far below highs. Zacks says now may be the time to buy these S&P 500 standouts for potential upside.
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
by Zacks Equity Research
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
2 S&P 500 Stocks to Buy Now On the Dip for Huge Upside
by Benjamin Rains
Diving into two beaten-down S&P 500 stocks--Thermo Fisher Scientific and Lululemon--to consider buying now for huge upside.
Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.